281 712

Cited 2 times in

Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment

Authors
 Hye Kyung Hyun  ;  Hyun-Soo Zhang  ;  Jongwook Yu  ;  Eun Ae Kang  ;  Jihye Park  ;  Soo Jung Park  ;  Jae Jun Park  ;  Tae Il Kim  ;  Won Ho Kim  ;  Jae Hee Cheon 
Citation
 BMC GASTROENTEROLOGY, Vol.22(1) : 143, 2022-03 
Journal Title
BMC GASTROENTEROLOGY
Issue Date
2022-03
MeSH
Biological Therapy ; Colitis, Ulcerative* / drug therapy ; Crohn Disease* / drug therapy ; Humans ; Retrospective Studies ; Tumor Necrosis Factor Inhibitors ; Tumor Necrosis Factor-alpha
Keywords
Anti-TNF therapy ; Crohn’s disease ; Tofacitinib ; Ulcerative colitis ; Ustekinumab ; Vedolizumab
Abstract
Background: Therapeutic options for inflammatory bowel disease (IBD) have increased since the introduction of tumour necrosis factor (TNF) inhibitors a few decades ago. However, direct comparisons of the effectiveness of second-line biological agents in patients with ulcerative colitis (UC) and Crohn's disease (CD) are lacking.

Methods: Patients with UC or CD who experienced anti-TNF treatment failure and subsequently used vedolizumab, ustekinumab, or tofacitinib as a second-line drug were retrospectively recruited. The primary outcomes were the clinical remission rate at week 16 and the cumulative relapse rate 48 weeks after receiving induction therapy.

Results: A total of 94 patients with UC or CD experienced anti-TNF treatment failure and received vedolizumab (UC: 37; CD: 28), ustekinumab (CD: 16), or tofacitinib (UC: 13). The clinical remission rates were not significantly different between the vedolizumab and tofacitinib groups in UC patients (56.8% vs. 46.2%, p = 0.509). In CD patients, the clinical remission rates were not significantly different between the vedolizumab and ustekinumab groups (53.6% vs. 50.0%, p = 0.820). Moreover, the cumulative rates of clinical relapse were not significantly different between the vedolizumab and tofacitinib groups in UC patients and between the vedolizumab and ustekinumab groups in CD patients (p = 0.396 and p = 0.692, respectively). Safety profiles were also similar among the treatment groups in both UC and CD patients.

Conclusions: After prior anti-TNF therapy failure, vedolizumab and tofacitinib in UC patients and vedolizumab and ustekinumab in CD patients were not significantly different in terms of the efficacy in inducing and maintaining a clinical response.
Files in This Item:
T202201476.pdf Download
DOI
10.1186/s12876-022-02225-w
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Eun Ae(강은애)
Kim, Won Ho(김원호) ORCID logo https://orcid.org/0000-0002-5682-9972
Kim, Tae Il(김태일) ORCID logo https://orcid.org/0000-0003-4807-890X
Park, Soo Jung(박수정)
Park, Jae Jun(박재준)
Park, Ji Hye(박지혜)
Yu, Jongwook(유종욱)
Cheon, Jae Hee(천재희) ORCID logo https://orcid.org/0000-0002-2282-8904
Hyun, Hye Kyung(현혜경)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/188550
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links